

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**HARBOUR**  
**B I O M E D**  
**和 鉑 醫 藥 控 股 有 限 公 司**  
**HBM Holdings Limited**  
*(incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 02142)**

**VOLUNTARY ANNOUNCEMENT**  
**DATA RELEASE FORECAST OF HBM4003 AT ASCO 2022**

This announcement is made by HBM Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business update of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that the Company will release the progress of our HBM4003 studies of monotherapy and combination therapy with anti-PD-1 antibody during the American Society of Clinical Oncology (“**ASCO**”) 2022 annual meeting.

**Abstract One**

Study title: A Phase I Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of HBM4003 in Subjects with Advanced Solid Tumors

Abstract number: #363712

Publication type: Poster

**Abstract Two**

Study title: A Phase I Open-label Study to Evaluate the Safety, Tolerability, PK/PD and Anti-tumor Activity of HBM4003 in Combination with Toripalimab in Subjects with Advanced Melanoma and Other Solid Tumors

Abstract number: #368316

Publication type: Abstract

HBM4003 has demonstrated strong efficacy and excellent safety profile of the drug. The Company will continue to be fully committed to advancing the global clinical development project of HBM4003, furthering its global innovation and development strategy in 2022. The Company believes that this product will have the potential to lead the development of next generation therapy of immuno-oncology, especially the combination therapy.

Harbour BioMed is developing HBM4003 as part of its broad and innovative immuno-oncology pipeline to address significant unmet medical need in many solid tumor indications.

## About HBM4003

HBM4003 is a fully human anti-CTLA-4 monoclonal heavy chain only antibody (HCAb) generated from Harbour Mice<sup>®</sup>. It is the first fully human heavy-chain-only monoclonal antibody entered into clinical stage globally. By enhancing antibody-dependent cell cytotoxicity (ADCC) killing activity, HBM4003 has demonstrated significantly improved depletion specific to high CTLA-4 expressing Treg cells in tumor tissues. The potent anti-tumor efficacy and differentiated pharmacokinetics with durable pharmacodynamic effect presents a favorable product profile. This novel and differentiated mechanism of action has the potential to improve efficacy while significantly reducing the toxicity of the drug in monotherapy and combination therapy.

**Cautionary Statement:** We cannot guarantee that we will be able to successfully develop or ultimately market HBM4003. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By order of the Board  
**HBM Holdings Limited**  
**Dr. Jingsong Wang**  
*Chairman and Executive Director*

Hong Kong, 10 May 2022

*As at the date of this announcement, the board of directors of the Company comprises Dr. Jingsong Wang and Mr. Xiaoxiang Chen as executive Directors; Mr. Yu Min Qiu, Mr. Junfeng Wang and Ms. Weiwei Chen as non-executive Directors; Dr. Robert Irwin Kamen, Dr. Xiaoping Ye and Mr. Ka Chi Yau as independent non-executive Directors.*